Pharmacy practice has changed significantly lately. The professionals have the chance to
contribute straightforwardly to patient consideration so as to lessen morbimortality identified …

Introduction: Development of a therapy for bone metastases is of paramount importance for
castration-resistant prostate cancer (CRPC). The osteomimetic properties of CRPC confer a …

Metastasis to bone is the leading cause of death from prostate cancer. Interaction between
tumor cells and bone cells can promote progression and influence tumor phenotype. It is …

Prostate cancer frequently metastasizes to bone, but bone marrow involvement is relatively
less common. In advanced prostate cancer, significant bone marrow infiltration can result in …

Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone
metastases: a Cochrane Review and network meta‐analysis - PMC Back to Top Skip to …

The present invention concerns methods for treating a prolif eration disorder, such as
prostate cancer, basal cell carci noma, lung cancer, and other cancers, using an inhibitor of …

Breast, lung, and prostate cancers are the three most common malignancies to metastasize
to the temporal bone. Still, metastatic prostate cancer of the temporal bone is a rare finding …

Prostate cancer is the most common noncutaneous cancer in males. Men of African origin
are at a significantly higher risk as reflected in the higher incidence and mortality rates in this …

Background Prostate cancer is among the leading causes of cancer-related death in men
[2]. Despite improvements in both its detection at early stages as well as effectiveness of …